Clinical Trial Update: A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia [Phase 3]

View source ↗

Summary

Phase 3 trial of MCI-196 in chronic kidney disease patients on dialysis with hyperphosphatemia and dyslipidemia completed; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Dyslipidemia
• Hyperphosphatemia

Drugs mentioned

• MCI-196

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Chronic Kidney Disease, Dialysis | Phase 3 | Status: COMPLETED | Results posted: 2014-10-06